Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436

Watchlist Manager
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Logo
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Watchlist
Price: 207.13 CNY -0.42% Market Closed
Market Cap: 125B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Zhangzhou Pientzehuang Pharmaceutical Co Ltd stock under the Base Case scenario is 148.93 CNY. Compared to the current market price of 207.13 CNY, Zhangzhou Pientzehuang Pharmaceutical Co Ltd is Overvalued by 28%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
148.93 CNY
Overvaluation 28%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

11.6
P/S
P/S
Price to Sales
11.6
vs History
90
vs Industry
12
Median 3Y
15.7
Median 5Y
18.9
Industry
2.4
Forward
10
More Details
41.6
P/E
P/E
Price to Earnings
41.6
vs History
88
vs Industry
11
Median 3Y
53.9
Median 5Y
67.2
Industry
20.3
Forward
34.5
More Details
73.6
P/OCF
P/OCF
Price to OCF
73.6
vs History
42
vs Industry
4
Median 3Y
61.1
Median 5Y
67.2
Industry
15.6
More Details
366.9
P/FCFE
P/FCFE
Price to FCFE
366.9
vs History
19
vs Industry
5
Median 3Y
62.2
Median 5Y
65
Industry
23.1
More Details
8.8
P/B
P/B
Price to Book Value
8.8
vs History
90
vs Industry
7
Median 3Y
11.7
Median 5Y
14.8
Industry
2
More Details
11.3
EV/S
EV/S
Enterprise Value to Sales
11.3
vs History
85
vs Industry
12
Median 3Y
15.6
Median 5Y
18.7
Industry
2.5
Forward
9.7
More Details
27.2
EV/GP
EV/GP
Enterprise Value to Gross Profit
27.2
vs History
82
vs Industry
8
Median 3Y
34.1
Median 5Y
40.6
Industry
4.8
More Details
35.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
35.3
vs History
85
vs Industry
10
Median 3Y
46.2
Median 5Y
57.5
Industry
12.5
Forward
27.8
More Details
35.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
35.3
vs History
85
vs Industry
13
Median 3Y
46.2
Median 5Y
57.5
Industry
15.7
Forward
31.5
More Details
71.4
EV/OCF
EV/OCF
Enterprise Value to OCF
71.4
vs History
42
vs Industry
4
Median 3Y
57.7
Median 5Y
66.8
Industry
14.1
More Details
216
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
216
vs History
23
vs Industry
4
Median 3Y
61.1
Median 5Y
71.4
Industry
17.6
More Details
10
EV/IC
EV/IC
Enterprise Value to IC
10
vs History
84
vs Industry
10
Median 3Y
14.8
Median 5Y
21.9
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Zhangzhou Pientzehuang Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
125B CNY 11.6 41.6 35.3 35.3
US
Eli Lilly and Co
NYSE:LLY
720.3B USD 14.6 64.6 34.9 38.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
375.8B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.6 18.9 12.5 14.2
CH
Roche Holding AG
SIX:ROG
206.7B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
178.5B CHF 4.1 16.8 10 13.4
UK
AstraZeneca PLC
LSE:AZN
157.1B GBP 3.8 26.9 130.3 196.4
US
Merck & Co Inc
NYSE:MRK
197.4B USD 3.1 11.3 8.1 9.8
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.3B USD 2.1 16.5 7.2 10.1
P/E Multiple
Earnings Growth PEG
CN
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Average P/E: 26.5
41.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.6
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.9
18%
1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
16.8
17%
1
UK
AstraZeneca PLC
LSE:AZN
26.9
36%
0.7
US
Merck & Co Inc
NYSE:MRK
11.3
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.5
29%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Average EV/EBITDA: 397.1
35.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.9
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
8%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.4
6%
1.6
CH
Novartis AG
SIX:NOVN
10
5%
2
UK
AstraZeneca PLC
LSE:AZN
130.3
9%
14.5
US
Merck & Co Inc
NYSE:MRK
8.1
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.